Clinical Trial Information Request for Protocol 24-095 Title Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone